ANDA 215621, held by Wilshire Pharmaceuticals. Formoterol Fumarate.
As of Nov 21, 2026, ANDA 215621 (Formoterol Fumarate), held by Wilshire Pharmaceuticals, was first approved by FDA on Dec 13, 2022, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 13, 2022 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Formoterol Fumarate0.02MG/2ML · solution;inhalation | Formoterol Fumarate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters